Vaxcyte, Inc. (PCVX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 03:30PM EDT. Market open.
| Previous close | 66.40 |
| Open | 66.40 |
| Bid | 67.28 x 100 |
| Ask | 67.57 x 100 |
| Day's range | 65.86 - 67.54 |
| 52-week range | 44.20 - 82.04 |
| Volume | |
| Avg. volume | 721,688 |
| Market cap | 7.334B |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.14 |
| Earnings date | 07 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 103.29 |
GuruFocus.comInsider Sale at Vaxcyte Inc: COO Jim Wassil Sells 3,000 Shares
On May 1, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte Inc (NASDAQ:PCVX), sold 3,000 shares of the company.
GlobeNewswireVaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media se
GuruFocus.comSutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances
Full Year Earnings Reveal Strong Revenue Growth but Operational Challenges Persist
© 2024 Yahoo. All rights reserved.